Multiple myeloma is a cancer of plasma cells in the bone marrow, causing bone pain, anemia, kidney damage, and recurrent infections. Symptoms arise from the accumulation of abnormal plasma cells.
Bortezomib is a proteasome inhibitor used in the treatment of hematological malignancies including multiple myeloma.
Lenalidomide is a proteasome inhibitor used in the treatment of hematological malignancies including multiple myeloma.
Describe your symptoms and get a structured AI clinical assessment — possible causes, urgency level, and recommended next steps.
Start Free AI Analysis →Content on this page is informed by evidence-based clinical sources including: